Modern treatment in chronic lymphocytic leukemia: impact on survival and efficacy in high-risk subgroups.

doi:10.1002/cam4.226

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Modern treatment in chronic lymphocytic leukemia: impact on survival and efficacy in high-risk subgroups.

Cancer medicine - 1 Jun 2014

Cuneo Antonio, Cavazzini Francesco, Ciccone Maria, Daghia Giulia, Sofritti Olga, Saccenti Elena, Negrini Massimo, Rigolin Gian Matteo

Abstract excerpt

Treatment of chronic lymphocytic leukemia (CLL) has dramatically changed over the last years, with significant improvement in overall survival (OS) and increased efficacy in genetically defined "high-risk" disease. Besides prospective clinical trials usually enrolling young and fit patients, retrospective studies were performed comparing the outcome of patients belonging to different age groups and showing longer...

Read the complete abstract on PubMed

Topics

Aged
Aged, 80 and over
Antibodies, Monoclonal, Humanized
Antineoplastic Combined Chemotherapy Protocols
Disease-Free Survival

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Female

Humans

Leukemia, Lymphocytic, Chronic, B-Cell

Male

Mutation

Prognosis

Proto-Oncogene Proteins c-bcl-2

Randomized Controlled Trials as Topic

Retrospective Studies

Tumor Suppressor Protein p53

Source

Open in PubMed Open full text

Identifiers

PMID: 24648042
DOI: 10.1002/cam4.226
PMCID: PMC4101746

Genes

BCL2
NOTCH1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Modern treatment in chronic lymphocytic leukemia: impact on survival and efficacy in high-risk subgroups.PMID 24648042Read ↗

Chronic Lymphocytic Leukemia: Prognostic/Predictive Factors in the Era of Novel DrugsSemantic proximity Read ↗

Risk-Adapted Therapy in Early-Stage Chronic Lymphocytic Leukemia.Semantic proximity Read ↗

Recent therapeutic advances in chronic lymphocytic leukemiaSemantic proximity Read ↗

Update on therapy of chronic lymphocytic leukemia.Semantic proximity Read ↗

[Chronic lymphocytic leukemia : treatment concepts in transition].Semantic proximity Read ↗

Prognostication in chronic lymphocytic leukemia.Semantic proximity Read ↗

High-risk chronic lymphocytic leukemia in the era of pathway inhibitors: integrating molecular and cellular therapiesSemantic proximity Read ↗

Predicting Prognosis in Chronic Lymphocytic Leukemia in the Contemporary Era.Semantic proximity Read ↗

Chronic Lymphocytic Leukemia: Molecular Pathologies and Therapeutic StrategiesSemantic proximity Read ↗

Understanding and managing ultra high-risk chronic lymphocytic leukemia.Semantic proximity Read ↗

Cytogenetic prioritization with inclusion of molecular markers predicts outcome in previously untreated patients with chronic lymphocytic leukemia treated with fludarabine or fludarabine plus cyclophosphamide: a long-term follow-up study of the US intergroup phase III trial E2997.Semantic proximity Read ↗

Modern and conventional prognostic markers of chronic lymphocytic leukaemia in the everyday haematological practice.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.